Kaykhosrow Hooshmand Parsi, MD
Internal Medicine · Pueblo, CONPI 1447291851
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $601, 4.8 times the $125 reported in 2019. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$270
- Indivior Inc.$269
- Amgen$207
- AbbVie$171
- Astellas Pharma US Inc$120
- AstraZeneca$100
- plus $913 from 23 others
What the payments were for
- Food & beverage$2,051100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $270 |
| Indivior Inc. | 17 | $269 |
| Amgen(2 entities) | 11 | $207 |
| AbbVie | 8 | $171 |
| Astellas Pharma US Inc | 5 | $120 |
| AstraZeneca | 6 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Grifols USA, LLC | 2 | $85 |
| Alkermes, Inc. | 5 | $82 |
| Idorsia Pharmaceuticals US Inc | 5 | $82 |
| Novartis | 4 | $77 |
| Lilly USA, LLC | 4 | $72 |
| Bayer | 3 | $57 |
| Exact Sciences | 3 | $44 |
| Eisai Inc. | 2 | $34 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| MDD US Operations, LLC | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Viiv Healthcare Company | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Tonix Medicines, Inc. | 1 | $19 |
| Braeburn Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
| USWM, LLC | 1 | $11 |
How this compares
$2,051 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 92 | $104,012 |
| OzempicSemaglutide | 72 | $93,196 |
| JardianceEmpagliflozin | 50 | $58,169 |
| EliquisApixaban | 31 | $23,556 |
| FarxigaDapagliflozin Propanediol | 18 | $14,509 |
| LinzessLinaclotide | 17 | $11,070 |
| XareltoRivaroxaban | 14 | $9,857 |
| Bydureon BciseExenatide Microspheres | 11 | $8,711 |
| InvokanaCanagliflozin | 13 | $8,128 |
| SavellaMilnacipran Hcl | 11 | $7,877 |
| TradjentaLinagliptin | 13 | $6,685 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 32 | $4,516 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $3,076 |
| Atorvastatin Calcium | 255 | $2,304 |
| Levemir FlexpenInsulin Detemir | 14 | $2,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $72 | $104,01292 claims |
| Novo NordiskOzempic | $270 | $93,19672 claims |
| AbbVieLinzess, Savella, Synthroid | $171 | $19,86639 claims |
| AstraZenecaFarxiga | $100 | $14,50918 claims |
| Indivior Inc.Suboxone | $269 | $3,07613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Pueblo
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
- Monica GrafalsAvon$401K
- Luke WebbColorado Springs$287K
- Samuel PiedadColorado Springs$154K
- Sophia AmbrusoLittleton$62K
- Kristine KuhnAurora$61K
- Kenneth OleszekDenver$60K
- Munni SelagamsettyColorado Springs$55K
- Robert KeithDenver$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.